A review of cannabis research confirmed increasing global use with highest prevalence among youth, mechanism similarities with opiates, evidence supporting gateway drug concerns, and growing evidence linking use to psychotic disorders.
Read this if you want a broad overview of what science says about cannabis risks across epidemiology, neuroscience, and mental health.
Social perception of low risk conflicts with biological evidence of cognitive and mental health harm
What the researchers found
The review synthesized evidence across three domains. Epidemiologically, cannabis use typically starts between ages 15-24 and decreases with adult responsibilities. The highest prevalence is in North America, Australia, and Europe.
Neurobiologically, cannabis shares some mechanism-of-action analogies with opiates. Clinical evidence supports concerns about the increased consumption among youth and the risk of psychotic disorder onset.
The review stated that cannabis intake during adolescence "may facilitate the transition to the use and/or abuse of other psychotropic drugs, hence properly being considered a 'gateway drug.'" The authors concluded that the social perception of low risk is at odds with biological and clinical evidence of cognitive impairment and mental health effects.
Why it matters
This review captures the tension between rising social acceptance and accumulating scientific evidence of harm, particularly for young users. The neurobiological parallels with opiates and the gateway drug discussion add important context to ongoing policy debates.
The numbers in context
Cannabis use prevalence: varies by income, highest in North America, Australia, Europe. Typical initiation: ages 15-24. Use decreases with acquisition of adult responsibilities.
How the study worked
Narrative review examining papers on epidemiological, neurobiological, and psychopathological aspects of cannabis use, searched through PubMed.
What this study cannot tell us
Narrative review without systematic methodology. The gateway drug framing is contested in the research community. The review does not adequately distinguish between moderate and heavy use in its risk assessments. Published in a pharmacology journal, which may emphasize biological concerns over social context.
How to read the evidence
Narrative review covering multiple research domains. Provides a useful overview but lacks systematic rigor and may overstate certain conclusions.
When this study was published
Published in 2017. The epidemiological landscape has continued to shift with legalization in multiple countries.
The bigger picture
The disconnect between public perception ("soft drug") and scientific evidence (cognitive impairment, psychosis risk, gateway effects) represents one of the central challenges in cannabis policy. This review highlights that the evidence for harm has grown even as social acceptance has increased.
Questions still open
- How does the risk profile change with different use patterns (occasional vs daily)? Do harm reduction approaches (lower potency, non-smoked routes) meaningfully reduce the risks described? Can the gateway drug effect be explained by shared predisposing factors rather than cannabis itself?
Common questions
Is cannabis really a gateway drug?
How does cannabis compare to opiates neurobiologically?
Read the original research
Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update.
CNS & neurological disorders drug targets, 16(5), 598-609
Citation
De Luca, Maria Antonietta; Di Chiara, Gaetano; Cadoni, Cristina; Lecca, Daniele; Orsolini, Laura; Papanti, Duccio; Corkery, John; Schifano, Fabrizio. (2017). Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update.. CNS & neurological disorders drug targets, 16(5), 598-609. https://doi.org/10.2174/1871527316666170413113246
Explore the wider topic
- Physical vs Psychological Cannabis Dependence: What Science Actually Shows
- The Gap Between Cannabis Perception and Science: Why What We Believe Outpaces What We Know
- Cannabis Use Disorder: Am I Addicted? Self-Assessment Guide
- Cross-Addiction After Quitting Weed: When One Habit Replaces Another
- Is Weed Addictive? What the Research Actually Shows
- Is Cannabis Addictive? What the DSM-5 and Brain Science Say
- Quitting Weed and Alcohol Together: What to Know About Dual Cessation
- Is Rehab Necessary for Weed? An Honest Assessment
- Signs You May Have Cannabis Use Disorder: An Honest Self-Assessment
- Weed Vape Pen Addiction: Why Vaping Makes It Harder to Quit